Categories: All postsCannabis

Planet 13 is experiencing unheard of growth, says Beacon Securities

Traffic numbers are in for the month of May for Nevada cannabis operation Planet 13 (Planet 13 Stock Quote, Chart CSE:PLTH) and they’re nothing short of outstanding, says Doug Cooper, analyst for Beacon Securities, who in a Wednesday report to clients reiterated his “Buy” recommendation and 12-month target of C$7.25, representing a projected return of 172 per cent at the time of publication.

Planet 13 said its pot SuperStore averaged 2,095 daily paying customers in May, up seven per cent from April and up 50 per cent from its November opening. The average ticket price was $90.63, up 1.1 per cent from April and up 14 per cent from November.

Cooper says that the combined traffic and ticket growth of eight per cent is “unheard of in the retail market.” Further, the analyst points out that in the state of Nevada, P13 has been growing its market share from 6.4 per cent in November to 9.2 per cent in March (and up to 12 per cent in Las Vegas’ Clark County). Cooper says that he can think of “no other company that has such a dominant market share within a rec-legal state.”

The company plans to open a cafe and bistro, which Cooper expects should help convert some of its daily customers (about 3,500 in May) who are not purchasing into buyers.

“P13 has clearly established itself as THE company in Nevada. It is a very attractive state and one in which multi-state operators need to establish themselves. P13 is incredibly undervalued not only on its own merits but also as its key strategic position. Wholesale revenue and lounge remain upsides to our model,” Cooper says.

Cooper is calling for fiscal 2019 revenue and Adjusted EBITDA of $82.1 million and $20.5 million, respectively, and fiscal 2020 revenue and Adjusted EBITDA of $109.5 million and $38.0 million, respectively.

Tagged with: plth
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

MediciNova is a buy, this analyst says

Roth Capital Partners analyst Boobalan Pachaiyappan says MediciNova (MediciNova Stock Quote, Chart, News, Analysts, Financials NASDAQ:MNOV) lead ALS drug could offer… [Read More]

2 minutes ago

Calian Group: Buy, Sell or Hold?

Calian Group (Calian Group Stock Quote, Chart, News, Analysts, Financials TSX:CGY) has signed a strategic partnership with Ukrainian defence technology… [Read More]

11 minutes ago

Cargojet is our “Canada Best Idea”, this analyst says

TD Cowen analyst Tim James says Cargojet’s (Cargojet Stock Quote, Chart, News, Analysts, Financials TSX:CJT) valuation does not reflect the… [Read More]

31 minutes ago

Telus is down but not out, this investor says

Newhaven Asset Management CEO and portfolio manager Ryan Bushell says Telus (Telus Stock Quote, Chart, News, Analysts, Financials TSX:T) looks… [Read More]

24 hours ago

Can Celestica keep the good times rolling?

TD Cowen analyst John Shao says longer-term demand visibility supports Celestica (Celestica Stock Quote, Chart, News, Analysts, Financials NYSE:CLS) as… [Read More]

24 hours ago

High Tide is Canada’s cannabis leader, this analyst says

Haywood Securities analyst Neal Gilmer says High Tide’s (High Tide Stock Quote, Chart, News, Analysts, Financials TSXV:HITI) record Q3 results… [Read More]

1 day ago